Eupraxia Pharmaceuticals Inc. (EPRX)
Recent Filing Index
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Cover Page | — |
|
| Statements | ||
| Consolidated Balance Sheets | — |
|
| Consolidated Balance Sheets (P) | — |
|
| Consolidated Statements of Operations and Comprehensive Loss | — |
|
| Consolidated Statements of Changes In Shareholders' Equity | — |
|
| Consolidated Statements of Changes In Shareholders' Equity (deficit) | — |
|
| Consolidated Statements of Cash Flows | — |
|
| Notes | ||
| Accounts Payable and Accrued Liabilities | — |
|
| Amounts Receivable | — |
|
| Auritec License Agreement | — |
|
| Basis of Presentation | — |
|
| Commitments | — |
|
| Commitments and Contingencies | — |
|
| Convertible Debt | — |
|
| Financial Instruments | — |
|
| General and Administrative Expenses | — |
|
| Government Grants and Assistance | — |
|
| Income Taxes | — |
|
| Interest Expense | — |
|
| Lease Liability | — |
|
| Loans Payable | — |
|
| Nature of Business and Going Concern | — |
|
| Property and Equipment | — |
|
| Research and Development Expenses | — |
|
| Right-of-use Asset | — |
|
| Segmented Information | — |
|
| Share Capital and Other Components of Equity | — |
|
| Subsequent Event | — |
|
| Summary of Significant Accounting Policies | — |
|
| Supplemental Disclosure With Respect To Cash Flows | — |
|